Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 102Thyroid Neoplasms 40Thyroid Cancer, Papillary 36Carcinoid Tumor 32Neoplasms 28Multiple Endocrine Neoplasia Type 1 22Adenocarcinoma, Follicular 22Thyroid Carcinoma, Anaplastic 21Neoplasm Metastasis 21Pituitary Neoplasms 20Carcinoma, Neuroendocrine 20Pheochromocytoma 19Carcinoma, Medullary 19Paraganglioma 17Carcinoma, Non-Small-Cell Lung 17Somatostatinoma 16Adrenocortical Carcinoma 16Pancreatic Neoplasms 14Carcinoma, Islet Cell 14Insulinoma 12Glucagonoma 12Adenoma, Islet Cell 12Gastrinoma 11Colorectal Neoplasms 11Breast Neoplasms 11Sarcoma 10Melanoma 10Gastro-enteropancreatic neuroendocrine tumor 10Carcinoma, Renal Cell 10Pituitary ACTH Hypersecretion 9

Interventions

gallium Ga 68 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × von Hippel-Lindau Disease × Endocrine × Clear all
NCT01967537 2019-11-19

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
341 enrolled 14 charts
EndocrineNET

von Hippel-Lindau Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡